Bavarian Nordic (OTCPK:BVNR.Y) - Stock Price, News & Analysis

BVNR.Y Stock Overview

Develops, manufactures, and commercializes life-saving vaccines. More details

BVNR.Y fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 85.4% below our estimate of its fair value

Earnings grew by 54.6% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 0.06% per year for the next 3 years

Bavarian Nordic A/S Competitors

MannKind

NasdaqGM:MNKD

US$1.9b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

ADMA Biologics

NasdaqGM:ADMA

US$4.5b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$3.1b

Price History & Performance

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	DKK 8.13
52 Week High	DKK 14.60
52 Week Low	DKK 6.86
Beta	1.58
11 Month Change	-22.83%
3 Month Change	-35.68%
1 Year Change	8.47%
33 Year Change	-46.86%
5 Year Change	-0.49%
Change since IPO	37.64%

Recent updates

Shareholder Returns

	BVNR.Y	US Biotechs	US Market
7D	-17.0%	-10.3%	-2.1%
1Y	8.5%	13.6%	29.6%

Return vs Industry: BVNR.Y underperformed the US Biotechs industry which returned 13.6% over the past year.

Return vs Market: BVNR.Y underperformed the US Market which returned 29.6% over the past year.

Price Volatility

Is BVNR.Y's price volatile compared to industry and market?
BVNR.Y volatility
BVNR.Y Average Weekly Movement	6.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BVNR.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BVNR.Y's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1992	1,609	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.

Bavarian Nordic A/S Fundamentals Summary

How do Bavarian Nordic's earnings and revenue compare to its market cap?
BVNR.Y fundamental statistics
Market cap	US$1.87b
Earnings (TTM)	US$157.86m
Revenue (TTM)	US$856.60m

11.9x

P/E Ratio

2.2x

P/S Ratio

Is BVNR.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BVNR.Y income statement (TTM)
Revenue	DKK 6.07b
Cost of Revenue	DKK 2.33b
Gross Profit	DKK 3.74b
Other Expenses	DKK 2.62b
Earnings	DKK 1.12b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 05, 2025

Earnings per share (EPS)	14.24
Gross Margin	61.57%
Net Profit Margin	18.43%
Debt/Equity Ratio	0.1%

How did BVNR.Y perform over the long term?

See historical performance and comparison

BVNR.Y Stock Overview

Rewards

Risk Analysis

Bavarian Nordic A/S Competitors

NasdaqGM:MNKD

US$1.9b

NasdaqCM:CPRX

US$2.5b

NasdaqGM:ADMA

US$4.5b

NasdaqGS:AGIO

US$3.1b

Price History & Performance

Recent News & Updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial